MS: Busting the Myths
May 30, 2024 | Advocacy, Treatments
At MSNZ we would like to understand more about patient experiences with infusion treatments. The first line Disease Modifying Treatment (DMT) options we have been successful in advocating for in NZ are considered some of the best in the world. […]
July 27, 2023 | Treatments
Image: myriam-zilles-unsplash Today, the World Health Organisation (WHO) added three Disease Modifying Treatments (DMTs) for Multiple Sclerosis (MS) onto its Essential Medicines List for the first time. Addressing the global MS movement, Prof Mai Sharawy, Chair of the Board of […]
September 14, 2022 | Advocacy, Progressive, Treatments
Currently, only approximately 1900 of the over 4130 New Zealanders diagnosed with MS are able to access funded Disease Modifying Therapies (DMTs). In particular, those with progressive forms of MS, Secondary (SPMS) and Primary Progressive MS (PPMS), have extremely limited […]
May 26, 2021 | Advocacy
Multiple Sclerosis NZ received several reports from concerned patients regarding the ambiguity of the Special Authority Criteria for DMTs. With the support of Dr John Mottershead, Pharmac were approached for clarification. Concern centred around whether bilateral aids qualify for use […]
August 18, 2017
The below disease modifying treatments (DMT’s) are available for the treatment of MS in New Zealand. First line treatments for Relapsing Remitting MS (funded) Ocrevus® (Ocrelizumab) Gilenya® (Fingolimod) Aubagio® (teriflunomide) Tecfidera® (Dimethyl fumarate) Tysabri® (Natalizumab) Second line treatments for […]